Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine GSK2321138A When Administered in Children

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs GSK 2321138A (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Mar 2013 Primary endpoint added as reported by ClinicalTrials.gov.
    • 22 Nov 2012 Results were presented at IDWeek in October 2012, according to a GlaxoSmithKline media release.
    • 22 Nov 2012 Primary endpoint 'Haemagglutin-inhibition-antibody-levels' in children aged 3-17 years has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top